This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Kendall Law Group Investigates Abraxis BioScience Inc. Merger For Shareholders

Kendall Law Group, led by a former federal judge and a former U.S. Attorney, is investigating Abraxis BioScience Inc. (NASDAQ: ABII) for shareholders in connection with the proposed merger with Celgene Corporation. The firm’s investigation seeks to determine whether Abraxis and its Board breached their fiduciary duties by entering into the agreement without properly shopping for a deal that would provide better value for shareholders. If you are an Abraxis shareholder and would like additional information about your rights, contact the Kendall Law Group at 877-744-3728 or by email at skendall@kendalllawgroup.com.

On June 30, 2010, the companies announced that they had entered into an agreement for Abraxis to be acquired by Celgene $2.9 billion transaction. According to the agreement, Abraxis shareholders will receive $58.00 and 0.2617 shares of Celgene for each ABII share owned, representing a 17 percent premium above Abraxis' last closing price of $61.31. Chairman and CEO Patrick Soon-Shiong and his wife Michele B. Soon-Shiong are each beneficial owners of at least 10% of Abraxis stock. Abraxis recently announced trial design information from its ongoing phase III registration trial for Abraxane in the treatment of melanoma along with favorable results from other ongoing phase II trials.

Kendall Law Group was founded by a former federal judge, includes a former United States Attorney, prosecutors and securities lawyers who are experienced in complex securities litigation. The national securities firm has been counsel in numerous merger and acquisition cases nationwide, including some of the largest transactions in the United States.



Copyright Business Wire 2010

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
AAPL $128.70 0.00%
FB $78.81 0.00%
GOOG $540.78 0.00%
TSLA $230.51 0.00%
YHOO $42.04 0.00%

Markets

DOW 18,070.40 +46.34 0.26%
S&P 500 2,114.49 +6.20 0.29%
NASDAQ 5,016.9290 +11.5380 0.23%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs